RxDoctor Payments Data

Craig Johnson, DO

Family Medicine · Brazil, INNPI 1295725851

Payments from drug & device makers

$432in general payments, 2019–2025

Across 23 payments — averaging $18.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$179
  • E.r. Squibb & Sons, L.L.C.$46
  • Daiichi Sankyo Inc.$45
  • Clovis Oncology, Inc.$23
  • Genmab U.S., Inc.$20
  • AbbVie$20
  • plus $99 from 6 others

What the payments were for

  • Food & beverage$37286%
  • Education$6114%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$432 in reported general payments places this provider in the 45th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$113,687
Medicare patients
350
Services billed
1,390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban772$262,366
Kesimpta PenOfatumumab18$167,589
XareltoRivaroxaban222$69,600
JardianceEmpagliflozin190$69,209
OtezlaApremilast21$49,697
Trelegy ElliptaFluticasone/Umeclidin/Vilanter58$38,987
TrulicityDulaglutide39$35,206
EntrestoSacubitril/Valsartan79$32,531
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog159$31,059
ArexvyRsvpref3 Antigen/As01e/Pf84$26,907
MyrbetriqMirabegron103$24,704
OzempicSemaglutide22$22,562
CreonLipase/Protease/Amylase17$21,778
VraylarCariprazine Hcl28$20,085
NuedextaDextromethorphan Hbr/Quinidine30$19,651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$18$69,600222 claims
AbbVieCreon, Vraylar, Restasis Multidose$20$51,46859 claims
AmgenOtezla$18$49,69721 claims
NovartisEntresto$179$32,53179 claims
MerckJanuvia$13$13,78639 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Brazil

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →